Difference between revisions of "POEMS syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "][" to "] [") |
Warner-admin (talk | contribs) m (Text replacement - "=Rd {" to "=Lenalidomide & Dexamethasone (Rd) {") |
||
| Line 19: | Line 19: | ||
=All lines of therapy= | =All lines of therapy= | ||
| − | ==Rd {{#subobject:dc6eae|Regimen=1}}== | + | ==Lenalidomide & Dexamethasone (Rd) {{#subobject:dc6eae|Regimen=1}}== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
Revision as of 23:53, 17 April 2021
| Section editor | |
|---|---|
 |
Andrew J. Cowan, MD University of Washington Seattle, WA  andrewcowanmd |
POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes
1 regimens on this page
1 variants on this page
|
Guidelines
EMN
- 2018: Gavriatopoulou et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias PubMed
All lines of therapy
Lenalidomide & Dexamethasone (Rd)
| back to top |
Rd: Revlimid (Lenalidomide) & low-dose dexamethasone
Regimen
| Study | Evidence |
|---|---|
| Nozza et al. 2017 | Phase II, <20 pts |
Targeted therapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
Supportive medications
- Aspirin 100 mg PO once per day
- LMWH in "intolerant" patients
- Cotrimoxazole 800 mg PO twice per day two days per week
28-day cycle for at least 6 cycles
References
- Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article contains verified protocol PubMed